Your browser doesn't support javascript.
loading
Supraventricular Arrhythmia Following Patent Foramen Ovale Percutaneous Closure.
Guedeney, Paul; Laredo, Mikael; Zeitouni, Michel; Hauguel-Moreau, Marie; Wallet, Thomas; Elegamandji, Benjamin; Alamowitch, Sonia; Crozier, Sophie; Sabben, Candice; Deltour, Sandrine; Obadia, Michaël; Benyounes, Nadia; Collet, Jean-Philippe; Rouanet, Stéphanie; Hammoudi, Nadjib; Silvain, Johanne; Montalescot, Gilles.
Afiliação
  • Guedeney P; Sorbonne Université, ACTION Study Group, INSERM UMRS_1166 Institut de Cardiologie, Pitié Salpêtrière (AP-HP), Paris, France.
  • Laredo M; Sorbonne Université, ACTION Study Group, INSERM UMRS_1166 Institut de Cardiologie, Pitié Salpêtrière (AP-HP), Paris, France.
  • Zeitouni M; Sorbonne Université, ACTION Study Group, INSERM UMRS_1166 Institut de Cardiologie, Pitié Salpêtrière (AP-HP), Paris, France.
  • Hauguel-Moreau M; INSERM U-1018, Department of Cardiology, Ambroise Paré Hospital, Assistance Publique-Hôpitaux de Paris, Boulogne, France.
  • Wallet T; Sorbonne Université, ACTION Study Group, INSERM UMRS_1166 Institut de Cardiologie, Pitié Salpêtrière (AP-HP), Paris, France.
  • Elegamandji B; Sorbonne Université, ACTION Study Group, INSERM UMRS_1166 Institut de Cardiologie, Pitié Salpêtrière (AP-HP), Paris, France.
  • Alamowitch S; Sorbonne Université, Service des Urgences Cérébro-Vasculaires, Hôpital Pitié-Salpétrière, AP-HP, Paris, France.
  • Crozier S; Sorbonne Université, Service des Urgences Cérébro-Vasculaires, Hôpital Pitié-Salpétrière, AP-HP, Paris, France.
  • Sabben C; Rothschild Foundation Hospital, Neurology Department, Paris, France.
  • Deltour S; Neurology Department, Raymond-Poincaré Hospital (AP-HP), Garches, France.
  • Obadia M; Rothschild Foundation Hospital, Neurology Department, Paris, France.
  • Benyounes N; Cardiology Department, Rothschild Foundation Hospital, Paris, France.
  • Collet JP; Sorbonne Université, ACTION Study Group, INSERM UMRS_1166 Institut de Cardiologie, Pitié Salpêtrière (AP-HP), Paris, France.
  • Rouanet S; Statistician Unit, StatEthic, ACTION Study Group, Levallois-Perret, France.
  • Hammoudi N; Sorbonne Université, ACTION Study Group, INSERM UMRS_1166 Institut de Cardiologie, Pitié Salpêtrière (AP-HP), Paris, France.
  • Silvain J; Sorbonne Université, ACTION Study Group, INSERM UMRS_1166 Institut de Cardiologie, Pitié Salpêtrière (AP-HP), Paris, France.
  • Montalescot G; Sorbonne Université, ACTION Study Group, INSERM UMRS_1166 Institut de Cardiologie, Pitié Salpêtrière (AP-HP), Paris, France. Electronic address: gilles.montalescot@aphp.fr.
JACC Cardiovasc Interv ; 15(22): 2315-2322, 2022 11 28.
Article em En | MEDLINE | ID: mdl-36008269
ABSTRACT

BACKGROUND:

Randomized studies have reported low rates of atrial fibrillation (AF) after patent foramen ovale (PFO) closure (<6%) but have relied on patient-reported symptomatic episodes, so the true incidence and timing of AF after PFO closure remain unknown.

OBJECTIVES:

The aim of this study was to prospectively determine the incidence, timing, and determinants of supraventricular arrhythmia following PFO closure on the basis of loop recorder monitoring.

METHODS:

Cardiac monitoring was proposed to all patients after PFO closure from June 2018 to October 2021 at a single center by means of implantable loop recorder monitoring in patients considered at higher risk for AF (age ≥ 55 years, associated cardiovascular risk factors, prior palpitations, or documented supraventricular ectopic activity) or 4-week external loop recorder monitoring in other patients. The primary endpoint was the incidence of AF, atrial flutter, or supraventricular tachycardia lasting >30 seconds within 28 days of the procedure. Determinants of the primary endpoint were assessed using a stepwise logistic regression model.

RESULTS:

A total of 225 patients were included. The primary endpoint occurred in 47 patients (20.9%), including 13 (9.9%) and 24 (28.9%) among patients monitored with external loop recorders and implantable loop recorders, respectively. Overall, the median delay from procedure to arrhythmia was 14.0 days (IQR 6.5-19.0 days), and one-half of these patients reported symptomatic episodes. Determinants of the primary endpoint were older age (adjusted OR 1.67 per 10-year increase; 95% CI 1.18-2.36), device left disc diameter ≥25 mm (adjusted OR 2.67; 95% CI 1.19-5.98) and male sex (adjusted OR 4.78; 95% CI 1.96-11.66).

CONCLUSIONS:

Using loop recorder monitoring for ≥28 days, supraventricular arrhythmia was diagnosed in 1 in 5 patients, with a median delay of 14 days, suggesting that this postprocedural event has so far been underestimated.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Flutter Atrial / Acidente Vascular Cerebral / Forame Oval Patente / Dispositivo para Oclusão Septal Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Flutter Atrial / Acidente Vascular Cerebral / Forame Oval Patente / Dispositivo para Oclusão Septal Idioma: En Ano de publicação: 2022 Tipo de documento: Article